Analytical Data
-
基因名
VSIG4
- Application
-
别名
VSIG4；CRIg；V-set and immunoglobulin domain-containing Protein 4
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y279
-
表达区间
20-283aa
-
氨基酸序列
RPILEVPESVTGPWKGDVNLPCTYDPLQGYTQVLVKWLVQRGSDPVTIFL RDSSGDHIQQAKYQGRLHVSHKVPGDVSLQLSTLEMDDRSHYTCEVTWQT PDGNQVVRDKITELRVQKLSVSKPTVTTGSGYGFTVPQGMRISLQCQARG SPPISYIWYKQQTNNQEPIKVATLSTLLFKPAVIADSGSYFCTAKGQVGS EQHSDIVKFVVKDSSKLLKTKTEAPTTMTYPLKATSTVKQSWDWTTDMDG YLGETSAGPGKSLPVDHHHHHH
-
分子量
30 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant Human PKP4 Protein，GST
Cat：PAX2000-10364
Recombinant Human BHLHB2 Protein，His
Cat：PA2000-5796
Protein Description
VSIG4, also known as V-set and immunoglobulin domain containing 4, is an immunoregulatory protein primarily expressed on dendritic cells and macrophages. Its significance has emerged from its role in modulating immune responses, particularly in the context of immune tolerance and suppression. Research reveals that VSIG4 interacts with the T cell receptor, inhibiting T cell activation and promoting regulatory T cell (Treg) differentiation, making it a critical factor in maintaining immune homeostasis. This has sparked interest in exploring its potential therapeutic applications, particularly in autoimmune diseases, cancer immunotherapy, and transplant acceptance. Understanding VSIG4's mechanisms and pathways could lead to novel strategies for enhancing immune tolerance and preventing excessive immune reactions. Recent studies have focused on the structural characteristics of VSIG4, aiming to elucidate its interaction dynamics with immune cells and explore its modulatory effects in various disease models. As a result, VSIG4 stands out as a promising target for innovative immunotherapies and provides insights into the complex regulation of the immune system.
